Other studies have also demonstrated that EBV miRNA BART 16 disrupt Type I IFN signaling pathway by down-regulating the expression of CREB-binding protein, a transcriptional activator of IFN, and hence suppressing host immune response against the virus 94, and EBV produces BART6-3p which interacts with miR 97, a cellular microRNA, to synergistically suppress the expression of interleukin-6 receptor (IL-6R), which is a receptor for several antiviral cytokines such as IFN-α, IL-12 and IL-27 95, to promote tumor progression in both epithelia cancers and lymphomas. The gene discussed is IL6R; the disease is cancer.